Results 191 to 200 of about 2,114,568 (336)

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

A DEVELOPMENTAL ANALYSIS OF THE LETHAL MUTANT L(2)GL OF DROSOPHILA MELANOGASTER BASED ON CYTOPHOTOMETRIC DETERMINATION OF NUCLEAR DESOXYRIBONUCLEIC ACID (DNA) CONTENT [PDF]

, 1957
Robert M. Welch
openalex   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia. [PDF]

Blood Adv
Boertjes EL, Vonk CM, Kavelaars FG, Engvall M, Nordin S, Beugelink L, Rijken M, Konijnenburg JML, Versluis J, Löwenberg B, Valk PJM.   +10 more
europepmc   +1 more source

Origin of mutants disputed

Nature, 1988
James J. Bull, Brian Charlesworth, Deborah Charlesworth   +2 more
openaire   +5 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors. [PDF]

Discov Oncol
Wang L, Wei D, Li S, Jiang S.
europepmc   +1 more source

NATURAL MUTATIONS IN INBRED LINES OF MAIZE AND THEIR HETEROTIC EFFECT. II. COMPARISON OF MOTHER LINE VS. MUTANT WHEN OUTCROSSED TO UNRELATED INBREDS [PDF]

, 1956
Josef F Schuler, G. F. Sprague
openalex   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Letter to the editor: The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma. [PDF]

ESMO Open
Zhang D, Liu Y, Li M, Zhou Y, Cai M.
europepmc   +1 more source